IP Library Granted Patent US 9,624,202
Granted Patent B2
US 9,624,202 · App. 15/271,581 · Granted Apr 18, 2017

Heterocyclic amides as kinase inhibitors

Inventor: Jae U. Jeong (Collegeville, PA)
Assignee: GlaxoSmithKline Intellectual Property Development Limited
C07D403/12A61K31/55A61K31/553C07D223/08C07D267/14C07D281/10C07D403/14C07D409/12C07D413/12C07D413/14C07D417/12C07D487/04C07D498/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,624,202
App. No.
15/271,581
Granted
Apr 18, 2017
Kind
B2
Abstract

Disclosed are compounds having the formula: wherein X, Y, Z 1 , Z 2 , Z 3 , Z 4 , R 5 , R A , m, A. L, and B are as defined herein, and methods of making and using the same.

Claims (28)

1. A compound which is:

or a tautomer thereof, or a pharmaceutically acceptable salt thereof.

2. A pharmaceutical composition comprising the compound, or a tautomer thereof, or pharmaceutically acceptable salt thereof, according to claim 1 and one or more pharmaceutically acceptable excipients.

3. A method of treating ulcerative colitis comprising administering a therapeutically effective amount of the compound, or a tautomer thereof, or pharmaceutically acceptable salt thereof, according to claim 1 to a human in need thereof.

4. A method of treating Crohn's disease comprising administering a therapeutically effective amount of the compound, or a tautomer thereof, or pharmaceutically acceptable salt thereof, according to claim 1 to a human in need thereof.

5. A method of treating rheumatoid arthritis comprising administering a therapeutically effective amount of the compound, or a tautomer thereof, or pharmaceutically acceptable salt thereof, according to claim 1 to a human in need thereof.

6. A method of treating psoriasis comprising administering a therapeutically effective amount of the compound, or a tautomer thereof, or pharmaceutically acceptable salt thereof, according to claim 1 to a human in need thereof.

7. A method of treating spondyloarthritis comprising administering a therapeutically effective amount of the compound, or a tautomer thereof, or pharmaceutically acceptable salt thereof, according to claim 1 to a human in need thereof.

8. A method of treating SoJIA comprising administering a therapeutically effective amount of the compound, or a tautomer thereof, or pharmaceutically acceptable salt thereof, according to claim 1 to a human in need thereof.

9. A method of treating osteoarthritis comprising administering a therapeutically effective amount of the compound, or a tautomer thereof, or pharmaceutically acceptable salt thereof, according to claim 1 to a human in need thereof.

10. A method of treating multiple sclerosis comprising administering a therapeutically effective amount of the compound, or a tautomer thereof, or pharmaceutically acceptable salt thereof, according to claim 1 to a human in need thereof.

11. A method of treating sepsis comprising administering a therapeutically effective amount of the compound, or a tautomer thereof, or pharmaceutically acceptable salt thereof, according to claim 1 to a human in need thereof.

12. A method of treating ischemia reperfusion injury of solid organs comprising administering a therapeutically effective amount of the compound, or a tautomer thereof, or pharmaceutically acceptable salt thereof, according to claim 1 to a human in need thereof.

13. A method of treating systemic inflammatory response syndrome comprising administering a therapeutically effective amount of the compound, or a tautomer thereof, or pharmaceutically acceptable salt thereof, according to claim 1 to a human in need thereof.

14. A compound which is:

or a tautomer thereof.

15. A pharmaceutical composition comprising the compound, or a tautomer thereof, according to claim 14 and one or more pharmaceutically acceptable excipients.

16. A method of treating ulcerative colitis comprising administering a therapeutically effective amount of the compound, or a tautomer thereof, according to claim 14 to a human in need thereof.

17. A method of treating Crohn's disease comprising administering a therapeutically effective amount of the compound, or a tautomer thereof, according to claim 14 to a human in need thereof.

18. A method of treating rheumatoid arthritis comprising administering a therapeutically effective amount of the compound, or a tautomer thereof, according to claim 14 to a human in need thereof.

19. A method of treating psoriasis comprising administering a therapeutically effective amount of the compound, or a tautomer thereof, according to claim 14 to a human in need thereof.

20. A method of treating spondyloarthritis comprising administering a therapeutically effective amount of the compound, or a tautomer thereof, according to claim 14 to a human in need thereof.

21. A method of treating SoJIA comprising administering a therapeutically effective amount of the compound, or a tautomer thereof, according to claim 14 to a human in need thereof.

22. A method of treating osteoarthritis comprising administering a therapeutically effective amount of the compound, or a tautomer thereof, according to claim 14 to a human in need thereof.

23. A method of treating multiple sclerosis comprising administering a therapeutically effective amount of the compound, or a tautomer thereof, according to claim 14 to a human in need thereof.

24. A method of treating sepsis comprising administering a therapeutically effective amount of the compound, or a tautomer thereof, according to claim 14 to a human in need thereof.

25. A method of treating ischemia reperfusion injury of solid organs comprising administering a therapeutically effective amount of the compound, or a tautomer thereof, according to claim 14 to a human in need thereof.

26. A method of treating systemic inflammatory response syndrome comprising administering a therapeutically effective amount of the compound, or a tautomer thereof, according to claim 14 to a human in need thereof.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 21, 2016
From: BANDYOPADHYAY, DEEPAK; EIDAM, PATRICK M.; GOUGH, PETER J.; HARRIS, PHILIP ANTHONY; JEONG, JAE U.; KANG, JIANXING; KING, BRYAN WAYNE; SHAH, AMI LAKDAWALA; LEISTER, LARA KATHRYN; MARQUIS, ROBERT W., JR.; RAHMAN, ATTIQ; RAMANJULU, JOSHI M.; SEHON, CLARK A.; SINGHAUS, ROBERT, JR.; ZHANG, DAOHUA
To: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
Reel/Frame 039817/0511 →
Continuity (4)
Continuation 14763183
Provisional Application 61790044 · Mar 15, 2013
Provisional Application 61765664 · Feb 15, 2013
Related Publication 20170008878A1 · Jan 12, 2017